GLP-1媒介のインスリン分泌を増強する
bioRxiv : the preprint server for biology
|August 20, 2025
まとめ
受容体活性調節タンパク質3 (RAMP3) は,グルカゴン類ペプチド1受容体 (GLP-1R) と相互作用し,そのシグナリングを変化させ,インスリン分泌を増大させる. この発見により,副作用が少ないGLP-1Rの治療法が改善される可能性があります.
科学分野:
- 内分泌学
- 分子薬理学
- Gタンパク質結合受容体 (GPCR) 信号伝達
背景:
- グルカゴン類ペプチド-1受容体 (GLP-1R) アゴニストは糖尿病と肥満に有効ですが,副作用を引き起こす.
- 受容体活性調節タンパク質 (RAMPs) は,GPCRのシグナル伝達と発現を調節し,望ましくない効果を軽減する戦略を提供します.
- GLP-1RとRAMPの相互作用を理解することは,より安全で効果的な治療法の開発に不可欠です.
研究 の 目的:
- GLP- 1Rと受容体活性調節タンパク質3 (RAMP3) の相互作用を調査する.
- RAMP3結合が GLP- 1Rの信号伝達経路と機能的結果にどのように影響するかを決定する.
- 代謝疾患に対するGLP-1R-RAMP3複合体の治療の可能性を調査する.
主な方法:
- GLP- 1RとRAMP3の相互作用を確認するための共免疫プレシピテーションアッセイ.
- カルシウム (Ca2+) 動員と循環型AMP (cAMP) 産生を測定する細胞ベースの測定法
- 異なるRAMP3発現の細胞におけるGLP-1刺激によるGタンパク質結合 (Gαs,Gαq,Gαi) の分析
- グルコースとインスリン耐性を評価するために,RAMP3ノックアウトマウスを用いた体内試験.
主要な成果:
- GLP-1Rは,細胞表面でRAMP3と機能的なヘテロダイマーを形成する.
- RAMP3の発現は,正規のcAMP生成からCa2+動員とGαq/Gαi結合にGLP-1Rシグナリングをシフトさせる.
- RAMP3の過剰発現はGLP-1媒介によるインスリン分泌を促進し,RAMP3のノックアウトマウスはグルコースとインスリン耐性を低下させる.
結論:
- RAMP3はGLP- 1Rの信号伝達の重要な調節体として作用し,その活動をインスリン分泌に偏移させます.
- GLP- 1R- RAMP3複合体は,潜在的に副作用を減らすために,血糖制御を改善するための有望な治療目標です.
- これらの発見は,RAMPの相互作用を考慮することによって,GLP-1Rを標的とする新薬の設計のための基礎を提供します.
関連する概念動画
Glucagon-like Receptor Agonists
415
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
415
Dipeptidyl Peptidase 4 Inhibitors
249
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
249
Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256


